TKNO
Alpha Teknova, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$7.80
+5.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 46.0M | 40.5M | 37.7M | 36.7M | 41.4M |
| Cost of Revenue | 29.5M | 27.1M | 30.5M | 26.4M | 23.9M |
| Gross Profit | 16.5M | 13.4M | 7.2M | 10.3M | 17.5M |
| Operating Expenses | |||||
| R&D Expense | 2.3M | 2.2M | 2.8M | 5.6M | 7.7M |
| SG&A Expense | 28.3M | 27.1M | 29.5M | 34.8M | 37.4M |
| General & Admin Expense | 19.9M | 20.3M | 23.1M | 25.4M | 28.3M |
| Selling & Marketing Expense | 8.4M | 6.8M | 6.3M | 9.3M | 9.2M |
| Other Expenses | 574.0K | 1.1M | 1.1M | 5.5M | 21.9M |
| Total Operating Expenses | 31.2M | 30.4M | 33.4M | 45.9M | 67.1M |
| Cost and Expenses | 60.7M | 57.5M | 63.9M | 72.2M | 91.1M |
| Operating Income (EBIT) | (15.0M) | (17.0M) | (26.1M) | (35.6M) | (49.7M) |
| Non-Operating | |||||
| Interest Income | 2.0K | — | — | — | 213.0K |
| Interest Expense | 423.0K | 710.0K | 687.0K | 833.0K | — |
| Net Interest Income | (680.0K) | (710.0K) | (687.0K) | (833.0K) | 213.0K |
| Other Non-Op Income/Expense | (921.0K) | (225.0K) | (687.0K) | (1.5M) | 268.0K |
| Non-Operating Income (excl Interest) | (11.0K) | (485.0K) | — | (4.4M) | (20.8M) |
| EBT (Pre-Tax Income) | (15.9M) | (17.2M) | (26.8M) | (37.1M) | (49.4M) |
| Income Tax Expense | 49.0K | 58.0K | (88.0K) | (298.0K) | (1.9M) |
| Bottom Line | |||||
| Net Income | (16.0M) | (17.3M) | (26.7M) | (36.8M) | (47.5M) |
| Earnings from Cont. Ops | (16.0M) | (17.3M) | (26.7M) | (36.8M) | (47.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (16.0M) | (17.3M) | (26.7M) | (36.8M) | (47.5M) |
| Per Share | |||||
| Basic EPS | ($0.30) | ($0.32) | ($0.57) | ($1.16) | ($1.69) |
| Diluted EPS | ($0.30) | ($0.32) | ($0.57) | ($1.16) | ($1.69) |
| Revenue Per Share | $0.86 | $0.76 | $0.81 | $1.15 | $1.47 |
| Shares | |||||
| Basic Shares Outstanding | 53.7M | 53.5M | 46.7M | 31.8M | 28.1M |
| Diluted Shares Outstanding | 53.7M | 53.5M | 46.7M | 31.8M | 28.1M |
| Profitability Metrics | |||||
| EBITDA | (10.2M) | (10.1M) | (19.6M) | (25.5M) | (25.7M) |
| D&A | 4.8M | 6.3M | 6.6M | 5.7M | 3.2M |
| EBIT | (11.8M) | (16.5M) | (26.1M) | (31.2M) | (28.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026